Molecular models of the procoagulant Factor VIIIa-Factor IXa complex

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 9, 2005, Pages 2044-2056

  Autin, L ^a   Miteva, M A ^a   Lee, W H ^a,d   Mertens, K ^b   Radtke, K P ^c,e   Villoutreix, B O ^a  

^a INSERM   (France)

^b SANQUIN RESEARCH   (Netherlands)

^c BAYER CORPORATION   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Biolex Therapeutics   (United States)

Author keywords

FIXa; FVIIIa; Homology modeling; Protein protein docking; Structure

Indexed keywords

BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; DOCKING PROTEIN;

ALGORITHM; ARTICLE; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS;

ALGORITHMS; BLOOD COAGULATION; CYSTEINE ENDOPEPTIDASES; FACTOR IXA; FACTOR VIIIA; HUMANS; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 30644476343     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01527.x     Document Type: Article

References (82)

1. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
2. Zaitseva I, Card G, Moshkov K, Bax B, Ralph A, Lindley P. The X-ray structure of human serum ceruloplasmin at 3.1 A: nature of the copper centres. J Biol Inorg Chem 1996; 1: 15-23.
3. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG. Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human cerulo-plasmin. Blood 1997; 89: 2413-21.
4. Gale AJ, Pellequer JL. An engineered interdomain disulflde bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003; 1: 1966-71.
5. Hakeos WH, Miao H, Sirachainan N, Kemball-Cook G, Saenko EL, Kaufman RJ, Pipe SW. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thromb Haemost 2002; 88: 781-7.
6. Adams TE, Hockin MF, Mann KG, Everse SJ. The crystal structure of activated protein C-inactivated bovine factor Va: implications for cofactor function. Proc Natl Acad Sci USA 2004; 101: 8918-23.
7. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-42.
8. Liu ML, Shen BW, Nakaya S, Pratt KP, Fujikawa K, Davie EW, Stoddard BL, Thompson AR. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000; 96: 979-87.
9. Knobe KE, Villoutreix BO, Tengborn LI, Petrini P, Ljung RC. Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations. Haemostasis 2000; 30: 268-79.
10. Stoilova-McPhie S, Villoutreix BO. Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002; 99: 1215-23.
11. Takeshima K, Smith C, Tait J, Fujikawa K. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003; 89: 788-94.
12. Purohit VS, Ramani K, Kashi RS, Durrani MJ, Kreiger TJ, Balasubramanian SV. Topology of factor VIII bound to phosphatidylserine-containing model membranes. Biochim Biophys Acta 2003; 1617: 31-8.
13. Saleh M, Peng W, Quinn-Allen MA, Macedo-Ribeiro S, Fuentes-Prior P, Bode W, Kane WH. The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis. Thromb Haemost 2004; 91: 16-27.
14. Di Scipio RG, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61: 1528-38.
15. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.
16. Hopfner KP, Lang A, Karcher A, Sichler K, Kopetzki E, Brandstetter H, Huber R, Bode W, Engh RA. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure Fold Des 1999; 7: 989-96.
17. Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stuart D. The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell 1995; 82: 131-41.
18. Huang M, Furie BC, Furie B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 2004; 279: 14338-46.
19. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA 1995; 92: 9796-9800.
20. Mutucumarana VP, Duffy EJ, Lollar P, Johnson AE. The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study. J Biol Chem 1992; 267: 17012-21.
21. Bajaj SP, Schmidt AE, Mathur A, Padmanabhan K, Zhong D, Mastri M, Fay PJ. Factor IXa: factor VIIIa interaction, helix 330-338 of factor ixa interacts with residues 558-565 and spatially adjacent regions of the a2 subunit of factor VIIIa. J Biol Chem 2001; 276: 16302-9.
22. Fernandez-Recio J, Totrov M, Abagyan R. ICM-DISCO docking by global energy optimization with fully flexible side-chains. Proteins 2003; 52: 113-7.
23. Xiang Z, Soto CS, Honig B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. Proc Natl Acad Sci USA 2002; 99: 7432-37.
24. Shenkin PS, Yarmush DL, Fine RM, Wang HJ, Levinthal C. Predicting antibody hypervariable loop conformation. I. Ensembles of random conformations for ringlike structures. Biopolymers 1987; 26: 2053-85.
25. Xiang Z, Honig B. Extending the accuracy limits of prediction for side-chain conformations. J Mol Biol 2001; 311: 421-30.
26. Abagyan RA, Batalov S. Do aligned sequences share the same fold? J Mol Biol 1997; 273: 355-68.
27. Fernandez-Recio J, Totrov M, Abagyan R. Soft protein-protein docking in internal coordinates. Protein Sci 2002; 11: 280-91.
28. Abagyan R, Totrov M, Kuznetsov D. ICM: a new method for structure modeling and design: applications to docking and structure prediction from the distorted native conformation. J Comp Chem 1994; 15: 488-506.
29. Wesson L, Eisenberg D. Atomic solvation parameters applied to molecular dynamics of proteins in solution. Protein Sci 1992; 1: 227-35.
30. Femandez-Recio J, Totrov M, Abagyan R. Screened charge electrostatic model in protein-protein docking simulations. Pac Symp Biocomput 2002: 552-63.
31. Cardozo T, Batalov S, Abagyan R. Estimating local backbone structural deviation in homology models. Comput Chem 2000; 24: 13-31.
32. Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. Nature 1996; 381: 272.
33. Maiorov V, Abagyan R. Energy strain in three-dimensional protein structures. Fold Des 1998; 3: 259-69.
34. Deleage G, Blanchet C, Geourjon C. Protein structure prediction. Implications for the biologist. Biochimie 1997; 79: 681-6.
35. Jeimy SB, Woram RA, Fuller N, Quinn-Allen MA, Nicolaes GA, Dahlback B, Kane WH, Hayward CP. Identification of the MMRN1 binding region within the C2 domain of human Factor V. J Biol Chem 2004; 279: 51466-71.
36. Spiegel Jr PC, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98: 13-9.
37. Yegneswaran S, Smirnov MD, Safa O, Esmon NL, Esmon CT, Johnson AE. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem 1999; 274: 5462-8.
38. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
39. Pratt KP, Qian J, Ellaban E, Okita DK, Diethelm-Okita BM, Conti-Fine B, Scott DW. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost 2004; 92: 522-8.
40. Marquette KA, Pittman DD, Kaufman RJ. A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem 1995; 270: 10297-303.
41. Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, Lavend'homme R, Johnson KM, Freson K, Scandella D, Saint-Remy JM, Vermylen J. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999; 93: 2267-73.
42. Jacquemin M, Benhida A, Peerlinck K, Desqueper B, Vander Elst L, Lavend'homme R, d'Oiron R, Schwaab R, Bakkus M, Thielemans K, Gilles JG, Vermylen J, Saint-Remy JM. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000; 95: 156-63.
43. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269: 20522-7.
44. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998; 273: 19049-54.
45. Jenkins PV, Dill JL, Zhou Q, Fay PJ. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry 2004; 43: 5094-101.
46. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glul811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J BioL Chem 1996; 271: 1935-40.
47. Bovenschen N, Boertjes RC, Van Stempvoort G, Voorberg J, Lenting PJ, Meijer AB, Mertens K. Low density lipoprotein receptor-related protein and Factor IXa share structural requirements for binding to the A3 domain of coagulation Factor VIII. J Biol Chem 2003; 278: 9370-9377.
48. Kolkman JA, Lenting PJ, Mertens K. Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity. Biochem J 1999; 339 (Pt 2): 217-21.
49. Mathur A, Bajaj SP. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa, (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. J Biol Chem 330; 1999: 18477-86.
50. Lefkowitz JB, Nuss R, Haver T, Jacobson L, Thompson AR, Manco-Johnson M. Factor IX Denver, ASN 346 → ASP mutation resulting in a dysfunctional protein with defective factor VIIIa interaction. Thromb Haemost 2001; 86: 862-70.
51. Rohlena J, Kolkman JA, Boertjes RC, Mertens K, Lenting PJ. Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein. J Biol Chem 2003; 278: 9394-401.
52. Hamaguchi N, Bajaj SP, Smith KJ, Stafford DW. The role of amino-terminal residues of the heavy chain of factor IXa in the binding of its cofactor, factor VIIIa. Blood 1994; 84: 1837-42.
53. Chang YJ, Wu HL, Hsu YC, Hamaguchi N, Shi GY, Shen MC, Lin SW. Discontinuous residues of factor IX constitute a surface for binding the anti-factor IX monoclonal antibody A-5. Thromb Res 2003; 111: 293-9.
54. Mathur A, Zhong D, Sabharwal AK, Smith KJ, Bajaj SP. Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2 + binding site, proteolysis in the autolysis loop, phospholipid, and factor X. J Biol Chem 1997; 272: 23418-26.
55. Yang L, Manithody C, Olson ST, Rezaie AR. Contribution of basic residues of the autolysis loop to the substrate and inhibitor specificity of factor IXa. J Biol Chem 2003; 278: 25032-38.
56. Schmidt AE, Bajaj SP. Structure-function relationships in Factor IX and Factor IXa. Trends Cardiovasc Med 2003; 13: 39-45.
57. Lenting PJ, Donath MJ, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 1994; 269: 7150-5.
58. O'Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem 1995; 270: 27087-92.
59. 2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. J Biol Chem 1996; 271: 25332-7.
60. Christophe OD, Lenting PJ, Kolkman JA, Brownlee GG, Mertens K. Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain. J Biol Chem 1998; 273: 222-7.
61. Persson KE, Villoutreix BO, Thamlitz AM, Knobe KE, Stenflo J. The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody. J Biol Chem 2002; 277: 35616-24.
62. Celie PH, Van Stempvoort G, Fribourg C, Schurgers LJ, Lenting PJ, Mertens K. The connecting segment between both epidermal growth factor-like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 domain. J Biol Chem 2002; 277: 20214-20.
63. Wilkinson FH, London FS, Walsh PN. Residues 88-109 of factor IXa arc important for assembly of the factor X activating complex. J Biol Chem 2002; 277: 5725-33.
64. Knobe KE, Persson KE, Sjorin E, Villoutreix BO, Stenflo J, Ljung RC. Functional analysis of the EGF-like domain mutations Pro55Ser and Pro55Leu, which cause mild hemophilia B. J Thromb Haemost 2003; 1: 782-90.
65. Blostein MD, Furie BC, Rajotte I, Furie B. The Gla domain of factor IXa binds to factor VIIIa in the tenase complex. J Biol Chem 2003; 278: 31297-302.
66. Lin SW, Smith KJ, Welsch D, Stafford DW. Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells. J Biol Chem 1990; 265: 144-50.
67. Chang JY, Monroe DM, Stafford DW, Brinkhous KM, Roberts HR. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest 1997; 100: 886-92.
68. Yang L, Manithody C, Rezaie AR. Localization of the heparin binding exosite of factor IXa. J Biol Chem 2002; 277: 50756-60.
69. Sheehan JP, Kobbervig CE, Kirkpatrick HM. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa. Biochemistry 2003; 42: 11316-25.
70. Sheehan JP, Yuan Q-P, Walke EN. ASH Abstract. 2004: 1716.
71. Norledge BV, Petrovan RJ, Ruf W, Olson AJ. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis. Proteins 2003; 53: 640-8.
72. Chen SW, Pellequer JL, Schved JF, Giansily-Blaizot M. Model of a ternary complex between activated factor VII, tissue factor and factor IX. Thromb Haemost 2002; 88: 74-82.
73. Wodak SJ, Mendez R. Prediction of protein-protein interactions: the CAPRI experiment, its evaluation and implications. Curr Opin Struct Biol 2004; 14: 242-9.
74. Vajda S, Camacho CJ. Protein-protein docking: is the glass half-full or half-empty? Trends Biotechnol 2004; 22: 110-6.
75. van Dijk AD, Boelens R, Bonvin AM. Data-driven docking for the study of biomolecular complexes. Febs J 2005; 272: 293-312.
76. Nogami K, Lapan KA, Zhou Q, Wakabayashi H, Fay PJ. Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain. J Biol Chem 2004; 279: 15763-71.
77. Celie PH, Van Stempvoort G, Jorieux S, Mazurier C, Van Mourik JA, Mertens K. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function. Br J Haematol 1999; 106: 792-800.
78. Huang M, Rigby AC, Morelli X, Grant MA, Huang G, Furie B, Seaton B, Furie BC. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Biol 2003; 10: 751-6.
79. O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 2000; 95: 1714-20.
80. Regan LM, Lamphear BJ, Huggins CF, Walker FJ, Fay PJ. Factor IXa protects factor VIIIa from activated protein C. Factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562. J Biol Chem 1994; 269: 9445-52.
81. Astermark J, Stenflo J. The epidermal growth factor-like domains of factor IX. Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the gamma-carboxyglutamic acid region. J Biol Chem 1991; 266: 2438-43.
82. Chang YJ, Wu HL, Hamaguchi N, Hsu YC, Lin SW. Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa. J Biol Chem 2002; 277: 25393-9.